|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||133.64 / 184.21|
Filing for ABP 980, a Biosimilar Candidate to Herceptin® (trastuzumab), Supported by Phase 3 Data in Patients With HER2-Positive Early Breast Cancer
FDA Priority Review Status Underscores Need to Reduce Heart Attacks and Strokes
U.S. stock futures turn higher on Tuesday following earnings from Alphabet.
Wall Street's first glimpse at the second quarter.
Try this bearishly biased, out-of-the-money put spread on the Nasdaq 100 ETF.
Aimovig is an Investigative Migraine-Specific Preventive Therapy Designed for Patients With High Unmet Need
Array to Advance Preclinical Program for Autoimmune Disorders
Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
First Amgen and Allergan Oncology Biosimilar Candidate to be Reviewed by U.S. FDA Advisory Committee
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone
BLINCYTO is the First-and-Only Bispecific T Cell Engager (BiTE®) Immunotherapy to Demonstrate Superior Overall Survival Versus Standard of Care Chemotherapy
Two Diagnostic Companies Will Receive Lab Space and Other Benefits at San Francisco Life Sciences Incubator
Sarah Hassan, daughter of pharmaceutical executive Fred Hassan, was ignored by Shkreli for nearly a year before she received returns on her original investment.
A tech selloff yields big Wall Street losses.
Vectibix Demonstrated an Improvement in Overall Survival in Patients With Wild-Type RAS Metastatic Colorectal Cancer
Tech, healthcare slide weighs on rest of markets.
Healthcare's slide weighs on rest of markets.
The iShares NASDAQ Biotechnology Index ended the five days ended Friday, June 23 up 26% to close at $370.74.